Expression of Epsilon Toxin from Clostridium perfringens Type D in E. coli Rosetta (DE3): Study on a New Vaccine Production

Maryam Adibi¹, Reza Pilechian Langroudi²* and Lida Abdolmohammadi Khiav²

¹Department of Quality Control, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Alborz, Karaj, Iran.
²Department of Anaerobic Vaccine Research and Production, Specialized Clostridia Research Laboratory, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Alborz, Karaj, Iran.

Authors’ contributions

This work was carried out in collaboration among all authors. Author RPL (the supervisor) designed the study, performed the statistical analysis and wrote the protocol. Author MA wrote the first draft of the manuscript. Author LAK managed the analyses of the study and managed the literature searches. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/MRJI/2020/v30i930264

ABSTRACT

Clostridium perfringens is a Gram-positive anaerobic bacterium which is divided based on major toxins into five types (A-E). C. perfringens type D causes fatal enterotoxaemia (pulpy kidney) in sheep and goats that causes heavy economic losses in domestic animals. However current enterotoxaemia vaccine has been effective in controlling of disease; Strategies for the development of effective vaccine can be achieved by the production of new generation experimental vaccines. The aim of this study was cloning and expression of epsilon toxin of C. perfringens type D in E. coli Rosetta (DE3) to improve of the immunity. Epsilon toxin gene was cloned into pJET1.2/blunt vector and pET22b (+) expression vector and finally transformed into E. coli Rosetta competent cells.
Epsilon toxin is one of the most potent toxins of Clostridia. Clostridia are anaerobic and spore-forming bacteria which are widespread in the environment and intestinal tract of human and animals. One of the most important genus of Clostridia is *C. perfringens*. *C. perfringens*, the causative agent of gastrointestinal diseases in animals and foodborne disease, gangrene and enteritis necroticans in human [1], have been studied in Iran by Rafiei and Ardehali since 1950 [2]. *C. perfringens* chromosome is a single circular with G+C content of approximately 25% and 3.6 Mbp [3]. *C. perfringens* has been classified into five types (A-E) based on major toxins [4]. *C. perfringens* type D is produced by epsilon toxin (etx), which causes fatal enterotoxaemia (pulpy kidney) in sheep and goats [5]. The toxin is secreted in the small intestine as a 33-kDa prototoxin which is activated by removal of 13 amino acids from N-terminal and 22 residues from C-terminal [6]. The accumulation of active toxin (29-kDa) increases the permeability of the animal intestinal resulted in damage of brain, lungs, and kidneys [7].

Epsilon toxin is one of the most potent toxins among bacterial toxin [8]. Vaccines have been proven to be effective against clostridial disease. Several kind of vaccine is used for immunization in animals such as bacterin-toxoids (current vaccine) toxoid and new generation vaccine. In 1992, epsilon gene of *C. perfringens* type D had been cloned, expressed in *Escherichia coli* (E. coli) and surveyed immunization in mice [9]. The result showed that recombinant vaccines resulted in neutralization toxin in mice [10]. In 2010, epsilon gene was also cloned and expressed in *E. coli* against pulpy kidney. The result showed that adequate immunity in ruminants [11]. *C. perfringens* is a model for genetic researches [12] PET22 as expression cloning and *E. coli* as host also has been used for cloning and engineering studies since years ago. So, the aim of this study was cloning and expression of epsilon toxin of *C. perfringens* type D in *E. coli* Rosetta (DE3) to improve the immunity. In this study, *Nde*I and *Xho*I enzymes were used for digestion which contains cut region.

**Keywords:** *C. perfringens*; epsilon gene; cloning; expression; pET22; *E. coli* Rosetta (DE3).

**1. INTRODUCTION**

Clostridia are anaerobic and spore-forming bacteria which are widespread in the environment and intestinal tract of human and animals. One of the most important genus of Clostridia is *C. perfringens*. *C. perfringens*, the causative agent of gastrointestinal diseases in animals and foodborne disease, gangrene and enteritis necroticans in human [1], have been studied in Iran by Rafiei and Ardehali since 1950 [2]. *C. perfringens* chromosome is a single circular with G+C content of approximately 25% and 3.6 Mbp [3]. *C. perfringens* has been classified into five types (A-E) based on major toxins [4]. *C. perfringens* type D is produced by epsilon toxin (etx), which causes fatal enterotoxaemia (pulpy kidney) in sheep and goats [5]. The toxin is secreted in the small intestine as a 33-kDa prototoxin which is activated by removal of 13 amino acids from N-terminal and 22 residues from C-terminal [6]. The accumulation of active toxin (29-kDa) increases the permeability of the animal intestinal resulted in damage of brain, lungs, and kidneys [7].

Epsilon toxin is one of the most potent toxins among bacterial toxin [8]. Vaccines have been proven to be effective against clostridial disease. Several kind of vaccine is used for immunization in animals such as bacterin-toxoids (current vaccine) toxoid and new generation vaccine. In 1992, epsilon gene of *C. perfringens* type D had been cloned, expressed in *Escherichia coli* (E. coli) and surveyed immunization in mice [9]. The result showed that recombinant vaccines resulted in neutralization toxin in mice [10]. In 2010, epsilon gene was also cloned and expressed in *E. coli* against pulpy kidney. The result showed that adequate immunity in ruminants [11]. *C. perfringens* is a model for genetic researches [12] PET22 as expression cloning and *E. coli* as host also has been used for cloning and engineering studies since years ago. So, the aim of this study was cloning and expression of epsilon toxin of *C. perfringens* type D in *E. coli* Rosetta (DE3) to improve the immunity. In this study, *Nde*I and *Xho*I enzymes were used for digestion which contains cut region.

**2. MATERIALS AND METHODS**

**2.1 Cultivation**

*C. perfringens* type D vaccine strain (CN409) used as the source of genomic DNA. For production of recombinant protein, a prokaryotic expression vector pET22b (+) (Novagen, Germany) was used. *E. coli* Rosetta (DE3) strain was applied as an expression host. *C. perfringens* type D vaccine strain was grown anaerobically in the liver extract medium using anoxomat (Mart® microbiology, Netherlands) at 37°C overnight. On the other hand *E. coli* strains were grown in LB broth medium under aerobic condition [13].

**2.2 Isolation of Genomic DNA**

Then bacterial cells were harvested by centrifugation and treated in TE containing 1 mg/ml lysozyme before 10% SDS and RNase-A (10 mg/ml) was added and incubated for 30 minutes at 37°C. Proteinase K (50 mg/ml) was added and incubated for 1 hour. Extraction with equivalent phenol and chloroform solution was done twice. Sodium acetate (1:10 V/V) and isopropanol (1 V/V) were added to mixture and incubated at -20°C for 20 minute at least. The DNA was then centrifuged for 10 minute at 12500 rpm in 4°C. Sediment of chromosomal DNA was washed in ethanol 70%, dried, and resuspended in TE buffer [14].

**2.3 Gene Amplification**

Primers were designed from nucleotide sequence of etx gene was retrieved in GenBank under accession number HQ179546 using oligo software. etx gene was amplified using forward (5′-AAT-CAT-ATG-AAA-AAA-AAT-CTT-GTA-AAA-AGT-3′) and reverse primers (5′-AAT-CTC-GAG-TTT-TAT-TCC-TGG-TGC-CTT-AAT-3′) and *Pfu* DNA polymerase (Fermentas, Germany).

PCR amplification was performed in total volume of 25 µl containing template DNA (100 ng), 1 µM for each primers (10 pmol/µl), 1.5 mM Mg²⁺,
200 μM each dNTP, 1X PCR buffer and 2 unit of Pfu DNA polymerase and distilled water. The following conditions were used including 95°C (5 min), followed by 30 cycles of denaturing step of 1 min at 95°C, annealing step of 1 min at 52°C and extension step of 3 min at 72°C, followed by final extension at 72°C for 15 minutes. The PCR product was analyzed by electrophoresis in 1% agarose gel containing ethidium bromide and visualized using transilluminator. The PCR product was purified using Gene JET Gel Extraction Kit (Fermentas, Germany). Then nucleotide sequencing was carried out by SEQLAB (Sequence Laboratories Goettingen GmbH).

2.4 Cloning of etx Gene

pJET1.2/blunt vector was ligated with amplified etx gene in order to production of pJETε then transformed into Top10 E. coli competent cell, and screening of recombinant E. coli Top10 clones was performed by colony PCR and antibiotic resistance (culture of suspension on LB-amp agar supplemented with ampicillin 100mg/ml) (Fermentas, Germany). The positive colonies and pET22b were digested using Ndel and Xhol enzymes (Fermentas, Germany), purified (using Gene JET™ Gel Extraction Kit) and ligated with T4 DNA Ligase at 16°C. Screening of recombinant expression vector was performed as previously described. After that, they E. coli/Rosetta strains were transformed using pET22ε [pET22 (+) epsilon] and screening of recombinant E. coli/Rosetta clones was also done by colony PCR. After purification, Sequencing was performed using Forward and Reverse primers. The results obtained by Chromas Lite and Blast software were compared with the gene sequence in GenBank.

Recombinant E. coli cells were grown in LB broth medium at 37°C with shaking for 0.6–0.7 OD 600 and followed by induction with IPTG (0.5, 1 and 1.5 mM) (Fermentas, Germany). Samples were collected every in three times. Finally, SDS-PAGE (Paya Pajouhesh, Iran) analysis was surveyed to confirm protein expression.

3. RESULTS

The result of electrophoresis showed that the length of PCR product was 984 bp (Fig. 1).

Amplified and purified etx gene (using Gene JET™ Gel Extraction Kit) was ligated into digested vector pJET1.2/blunt and transformed Top10 E. coli successfully. The colony PCR and antibiotic resistance result confirmed the presence of the inserted fragment (Figs. 2, 3).

The result of restriction enzyme analysis of the plasmid DNA from the positive clones also confirmed the presence of the insert (Fig. 4).

After successful subcloning of the pET22ε, E. coli Rosetta competence cells were transformed in this vector. The colony PCR result also confirmed its. Sequencing result revealed that sequence of inserted gene was consistent accession number HQ179546 (99%). The result of SDS-PAGE showed that the optimum expression of recombinant protein was obtained with 0.5 mM IPTG and incubation time 3 h (Fig. 5).

4. DISCUSSION

C. perfringens causes severe economic losses in livestock and poultry industries, and wild life. Some Clostridium is the cause of disease in animals due to the release of exotoxins (e. g. alpha (cpa), beta (cpb), epsilon (etx), and iota (ia) [15]. This toxin causes enterotoxaemia in sheep and goats [16]. In 1954, the first strain of C. perfringens type D was isolated from intestinal contents of enterotoxaemia of sheep and goats.
Further research has shown widespread infection for years all over the country. Vaccination seems to be an effective way to control clostridial diseases [18]. *C. perfringens* is a suitable model for cloning and engineering studies [12] for production of new generation vaccine. So, the aim of this study was cloning and expression of epsilon toxin of *C. perfringens* type D in *E. coli* Rosetta (DE3) in order that improves of the immunity.

In this research the cloning vector was used pJET1.2/ blunt which is a 2974 bp linear plasmid. This vector has advantages over other vectors because these vectors with the use of Pfu enzyme which has proof reading activity, ligation can be corrected completed. This vector contains a lethal gene at the distance of 372-371 bp which will be destroyed cells [19] but after insertion of foreign fragment into cloning site, the ability of propagate will be survived. So, there is no need to observe the blue and white colonies. This vector has an extensive Multiple Cloning Site which has T7 promoter and an ampicillin resistance gene. During ligation, DNA is inserted at the end of the vector, which contains the 5-phosphoryl group, to form a recombinant circular plasmid of 3958 bp. After transformation, only transformed bacteria will grow in the LB agar plus ampicillin medium. After this step, the colonies were examined. The result of colony PCR showed 984 bp fragments which confirmed the previous result.

![Fig. 2. Positive colonies screened using colony PCR](image)

*Fig. 2. Positive colonies screened using colony PCR*

*Lanes 1-5, PCR product epsilon toxin C. perfringens type D, lane 6, 100 bp plus DNA size marker*

![Fig. 3. Positive colonies screened with antibiotic resistance (LB agar supplemented with ampicillin 100 mg/ml)](image)

*Fig. 3. Positive colonies screened with antibiotic resistance (LB agar supplemented with ampicillin 100 mg/ml)*

*Numbers 2-9 resistant to ampicillin and numbers 1, 10 sensitive to ampicillin*
In this study, *NdeI* and *XhoI* enzymes were used for digestion which contains cut region. *XhoI* and *NdeI* enzymes at the end of 5′ and 3′ of the gene has restriction site, respectively. The enzyme-digested and undigested plasmids were loaded on the agarose gel. The result showed that several clear bands more than 3 kb and one band more than 0.9 kb were observed in the undigested plasmid but only one sharp band approximately 2 kb (2974 bp), and epsilon toxin band (about 984 bp) were observed in the digested plasmid. These findings suggest that the epsilon toxin gene was inserted into the recombinant vector successfully.

After successful cloning of the pET22ε, *E. coli* Rosetta/ε competence cells were transformed in this vector. The colony PCR result confirmed that epsilon-toxin was transformed into the *E. coli* Rosetta/ε bacteria. Sequencing result also were consistent with the sequences reported in GenBank under accession number HQ179546 (99%).
Some recombinant vaccines have been prepared and evaluated in animals [20,21]. Souza et al. cloned the epsilon toxin into vector pET-11a and expressed. The result of study was successfully for animal immunization [10]. Nagahama et al. have perviously cloned the cpa gene and evaluated. The result was protective in mice [22]. Tang et al. cloned and sequenced enterotoxin (cpe) from C. perfringens type C [23]. Furthermore, recombinant vaccines against cpe from C. perfringens type A strain did not show any side effect on mice and guinea pigs [24]. Experimental recombinant vaccine Iota and TpeL have been expressed in E. coli [25,26]. Moreover, it has been reported that recombinant NetB vaccine is effective against enteritis necrotic in birds [27]. In other hand, recombinant multivalent vaccines also have been prepared and compared to the conventional vaccines [28, 29,30]. In this research the optimum expression of recombinant protein was obtained with 0.5 mM IPTG and incubation time between 2 and 4 h which is consistent with previously study [31]. Our study showed that the epsilon gene of C. perfringens type D can be cloned and expressed in E. coli Rosetta successfully.

5. CONCLUSION

In Conclusions the results obtained showed that this can be a suitable candidate as a recombinant vaccine for prevention of clostridial diseases. It is purposed more research on recombinant vaccine development be done in the future. It is hoped that in the future with further researches, the recombinant vaccine may replace the current vaccine.

ACKNOWLEDGEMENT

The authors wishes to express their warm thanks to all of the scientific members and staffs of anaerobic vaccine production department of Razi Vaccine and Serum Research Institute.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Petit L, Gibert M, Popoff MR. Clostridium perfringens: toxino type and genotype. Trends Microbiol. 1999;7(3):104-110.
2. Ardehali M, Darakhshan H, Moosawi M. The existence and present situation of clostridial diseases of domestic animals in Iran. Arch Razi Inst. 1984; 34(35):27-32.
3. Canad B, Saint-Joanis B, Cole S. Genomic diversity and organization of virulence genes in the pathogenic anaerobe Clostridium perfringens. Mol Microbiol. 1992;6(11):1421-1429.
4. Yoo HS, Lee SU, Park KY, Park YH. Molecular typing and epidemiological survey of prevalence of Clostridium perfringens types by multiplex PCR. J Clin Microbiol. 1997;35(1):228-232.
5. Uzal FA, Freedman JC, Shrestha A, Theoret JR, Garcia J, Awad MM, et al. Towards an understanding of the role of Clostridium perfringens toxins in human and animal disease. Future Microbiol. 2014;9(3):361-377.
6. Miyata S, Matsushita O, Minami J, Katayama S, Shimamoto S, Okabe A. Cleavage of a C-terminal peptide is essential for heptamerization of Clostridium perfringens ε-toxin in the synaptosomal membrane. J Biol Chem. 2001;276(17):13778-13783.
7. Popoff MR. Epsilon toxin: a fascinating pore-forming toxin. FEBS J. 2011;278(23):4602-4615.
8. Alves GG, de Avila RA, Chávez-Olórteguí CD, Lobato FCF. Clostridium perfringens epsilon toxin: the third most potent bacterial toxin known. Anaerobe. 2014;30:102-107.
9. Hunter S, Clarke IN, Kelly DC, Titball RW. Cloning and nucleotide sequencing of the Clostridium perfringens epsilon-toxin gene and its expression in Escherichia coli. Infect Immun. 1992;60(1):102-110.
10. Souza AM, Reis JKP, Assis RA, Horta CC, Siqueira FF, Facchin S, et al. Molecular cloning and expression of epsilon toxin from Clostridium perfringens type D and tests of animal immunization. Gene Mol Res. 2010;9(1):266-276.
11. Lobato FC, Lima CGRD, Assis RA, Pires PS, Silva ROS, Salvarani FM, et al. Potency against enterotoxemia of a recombinant Clostridium perfringens type D epsilon toxoid in ruminants. Vaccine. 2010;28(38):6125-6127.
12. Shimizu T, Ohtani K, Hirakawa H, Ohshima K, Yamashita A, Shiba T, et al. Complete genome sequence of *Clostridium perfringens*, an anaerobic flesh-eater. Natl Acad Sci. 2002;99(2):996-1001.

13. Hanahan D. Studies on transformation of *E. coli* with plasmids. J Mol Biol. (1983);166(4):557-80.

14. Hochulli E, Dobeli H, Schacher A. New metal chelate adsorbent selective for proteins and peptides containing neighbouring histidine residues. J Chromatogr. 1987;41:177-184.

15. Kiu R, Hall LJ. An update on the human and animal enteric pathogen *Clostridium perfringens*. Emerg Microbes Infect. 2018;7:1-15.

16. Cavalcanti MTH, Porto T, Porto ALF, Brandi IV, de Lima Filho JL, Junior AP. Large scale purification of *Clostridium perfringens* toxins: a review. Rev Bras Ciên Farm. 2004;40(2):151-164.

17. Ardehal M, Dowran H. Isolation of *Clostridium septicum* from cases of malignant oedema of cattle in Iran. Arch Razi Ins. 1969;21(1):67-72.

18. Springer S, Selbitz HJ. The control of necrotic enteritis in sucking piglets by means of a *Clostridium perfringens* toxoid vaccine. FEMS Immunol Med Microbiol. 1999;24(3):333-336.

19. Langroudi RP, Shamsara M, Aghaiypour K. Expression of *Clostridium perfringens* epsilon-beta fusion toxin gene in *E. coli* and its immunologic studies in mouse. Vaccine. 2013;31(32):3295-3299.

20. Hosomi K, Hinenoya A, Suzuki H, Nagatake T, Nishino T, Tojima Y, et al. Development of a bivalent food poisoning vaccine: augmented antigenicity of the C-terminal of *Clostridium perfringens* enterotoxin by fusion with the B subunit of *Escherichia coli* Shiga toxin 2. Int Immunol. 2019;31(2):91-100.

21. Rostami A, Goshadrou F, Langroudi RP, Bathiae SZ, Riazi A, Amani J, et al. Design and expression of a chimeric vaccine candidate for avian necrotic enteritis. Protein Eng Des Sel. 2017;30(1):39-45.

22. Nagahama M, Oda M, Kobayashi K, Ochi S, Takagishi T, Shibutani M, et al. A recombinant carboxy-terminal domain of alpha-toxin protects mice against *Clostridium perfringens*. Microbiol Immunol. 2013;57(5):340-345.

23. Tang Y, Wen M, Lian B, Cheng J, Wang K, Zhou B, et al. Detection, cloning, and sequencing of the enterotoxin gene of *Clostridium perfringens* type C isolated from goat. Turk J Vet Anim Sci. 2012;36(2):153-158.

24. Taherian Fard A, Hasan F, Bandehpour M, Mosaffa N, Mashhadi Abbas F, Hameed A, et al. Cloning and expression of C-terminal of *Clostridium perfringens* type A enterotoxin and its biological activity. Afr J Microbiol Res. 2010;4(14):1469-1474.

25. Mamandi H, Golestani Eimani B, Pilehchian Langroudi R. Cloning of *Tpel* Gene of *Clostridium perfringens* in *E. coli*. Modares J Biotechnol. 2019;10(1):103-107.

26. Seyed Sayyah P, Golestani Eimani B, Pilehchian Langroudi R. Cloning of *Clostridium perfringens* iota Toxin Gene in *Escherichia coli*. Arch Razi Inst. 2018;73(2):107-111.

27. Keyburn AL, Portela RW, Sproat K, Ford ME, Bannam TL, Yan X, et al. Vaccination with recombinant NetB toxin partially protects broiler chicks from necrotic enteritis. Vet Res. 2013;44(1):54.

28. Goossens E, Verherstraeten S, Valgaeren BR, Pardon B, Timbermont L, Schauvliege S, et al. The C-terminal domain of *Clostridium perfringens* alpha toxin as a vaccine candidate against bovine necrohemorrhagic enteritis. Vet Res. 2016;47:52.

29. Moreira GMSG, Salvareni FM, da Cunha CEP, Mendonça M, Moreira AN, Gonçalves LA, et al. Immunogenicity of a trivalent recombinant vaccine against *Clostridium perfringens* alpha, beta, and epsilon toxins in farm ruminants. Sci Rep. 2016;6:22816.

30. Salvareni FM, Conceição FR, Cunha CEP, Moreira GMSG, Pires PS, Silva ROS, et al. Vaccination with recombinant *Clostridium perfringens* toxoids α and β promotes elevated antipartum and passive humoral immunity in swine. Vaccine. 2013;31(38):4152-4155.
31. Steinthorsdottir V, Fridriksdottir V, perfringens beta-toxin glutathione S-Gunnarsson E, Andrésson OS. transferase fusion protein. FEMS Microbiol Expression and purification of Clostridium Lett. 1996;1(2-3):273-278.